Medline (MDLN) Competitors

Medline logo
$37.68 -1.49 (-3.80%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$37.55 -0.13 (-0.34%)
As of 11/17/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MDLN vs. ALC, WST, SOLV, COO, and ALGN

Should you buy Medline stock or one of its competitors? Medline's main competitors and comparable companies include Alcon (ALC), West Pharmaceutical Services (WST), Solventum (SOLV), Cooper Companies (COO), and Align Technology (ALGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does Medline compare to Alcon?

Medline (NASDAQ:MDLN) and Alcon (NYSE:ALC) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

In the previous week, Alcon had 1 more articles in the media than Medline. MarketBeat recorded 17 mentions for Alcon and 16 mentions for Medline. Medline's average media sentiment score of 0.89 beat Alcon's score of 0.30 indicating that Medline is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Medline
6 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alcon
4 Very Positive mention(s)
2 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

53.9% of Alcon shares are held by institutional investors. 0.8% of Medline shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Medline has higher revenue and earnings than Alcon. Alcon is trading at a lower price-to-earnings ratio than Medline, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medline$28.43B1.74$1.16B$0.4485.64
Alcon$10.40B3.53$980M$1.3754.16

Alcon has a net margin of 6.06% compared to Medline's net margin of 1.84%. Medline's return on equity of 8.21% beat Alcon's return on equity.

Company Net Margins Return on Equity Return on Assets
Medline1.84% 8.21% 4.03%
Alcon 6.06%7.54%5.25%

Medline presently has a consensus target price of $46.08, indicating a potential upside of 22.28%. Alcon has a consensus target price of $82.16, indicating a potential upside of 10.72%. Given Medline's stronger consensus rating and higher probable upside, analysts clearly believe Medline is more favorable than Alcon.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medline
2 Sell rating(s)
4 Hold rating(s)
23 Buy rating(s)
0 Strong Buy rating(s)
2.72
Alcon
1 Sell rating(s)
6 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.63

Summary

Medline beats Alcon on 9 of the 16 factors compared between the two stocks.

How does Medline compare to West Pharmaceutical Services?

Medline (NASDAQ:MDLN) and West Pharmaceutical Services (NYSE:WST) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

93.9% of West Pharmaceutical Services shares are held by institutional investors. 0.8% of Medline shares are held by insiders. Comparatively, 0.6% of West Pharmaceutical Services shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Medline presently has a consensus price target of $46.08, suggesting a potential upside of 22.28%. West Pharmaceutical Services has a consensus price target of $424.67, suggesting a potential upside of 2.58%. Given Medline's higher possible upside, analysts clearly believe Medline is more favorable than West Pharmaceutical Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medline
2 Sell rating(s)
4 Hold rating(s)
23 Buy rating(s)
0 Strong Buy rating(s)
2.72
West Pharmaceutical Services
0 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.93

In the previous week, Medline had 11 more articles in the media than West Pharmaceutical Services. MarketBeat recorded 16 mentions for Medline and 5 mentions for West Pharmaceutical Services. West Pharmaceutical Services' average media sentiment score of 1.04 beat Medline's score of 0.89 indicating that West Pharmaceutical Services is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Medline
6 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
West Pharmaceutical Services
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

West Pharmaceutical Services has a net margin of 18.81% compared to Medline's net margin of 1.84%. West Pharmaceutical Services' return on equity of 21.78% beat Medline's return on equity.

Company Net Margins Return on Equity Return on Assets
Medline1.84% 8.21% 4.03%
West Pharmaceutical Services 18.81%21.78%15.99%

Medline has higher revenue and earnings than West Pharmaceutical Services. West Pharmaceutical Services is trading at a lower price-to-earnings ratio than Medline, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medline$28.43B1.74$1.16B$0.4485.64
West Pharmaceutical Services$3.07B9.38$493.70M$8.9146.46

Summary

West Pharmaceutical Services beats Medline on 9 of the 15 factors compared between the two stocks.

How does Medline compare to Solventum?

Medline (NASDAQ:MDLN) and Solventum (NYSE:SOLV) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

In the previous week, Medline had 12 more articles in the media than Solventum. MarketBeat recorded 16 mentions for Medline and 4 mentions for Solventum. Medline's average media sentiment score of 0.89 beat Solventum's score of 0.80 indicating that Medline is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Medline
6 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Solventum
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Solventum has a net margin of 1.91% compared to Medline's net margin of 1.84%. Solventum's return on equity of 25.03% beat Medline's return on equity.

Company Net Margins Return on Equity Return on Assets
Medline1.84% 8.21% 4.03%
Solventum 1.91%25.03%8.65%

Medline currently has a consensus target price of $46.08, indicating a potential upside of 22.28%. Solventum has a consensus target price of $90.27, indicating a potential upside of 4.68%. Given Medline's stronger consensus rating and higher possible upside, equities analysts clearly believe Medline is more favorable than Solventum.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medline
2 Sell rating(s)
4 Hold rating(s)
23 Buy rating(s)
0 Strong Buy rating(s)
2.72
Solventum
1 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.71

Solventum has lower revenue, but higher earnings than Medline. Medline is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medline$28.43B1.74$1.16B$0.4485.64
Solventum$8.33B1.76$1.56B$0.8996.89

Summary

Solventum beats Medline on 8 of the 14 factors compared between the two stocks.

How does Medline compare to Cooper Companies?

Cooper Companies (NASDAQ:COO) and Medline (NASDAQ:MDLN) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

Cooper Companies has a net margin of 13.46% compared to Medline's net margin of 1.84%. Cooper Companies' return on equity of 10.90% beat Medline's return on equity.

Company Net Margins Return on Equity Return on Assets
Cooper Companies13.46% 10.90% 7.24%
Medline 1.84%8.21%4.03%

24.4% of Cooper Companies shares are owned by institutional investors. 2.1% of Cooper Companies shares are owned by insiders. Comparatively, 0.8% of Medline shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Medline has higher revenue and earnings than Cooper Companies. Cooper Companies is trading at a lower price-to-earnings ratio than Medline, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cooper Companies$4.09B2.82$374.90M$2.9320.72
Medline$28.43B1.74$1.16B$0.4485.64

Cooper Companies currently has a consensus price target of $68.60, indicating a potential upside of 12.98%. Medline has a consensus price target of $46.08, indicating a potential upside of 22.28%. Given Medline's stronger consensus rating and higher probable upside, analysts clearly believe Medline is more favorable than Cooper Companies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cooper Companies
3 Sell rating(s)
12 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.05
Medline
2 Sell rating(s)
4 Hold rating(s)
23 Buy rating(s)
0 Strong Buy rating(s)
2.72

In the previous week, Cooper Companies had 11 more articles in the media than Medline. MarketBeat recorded 27 mentions for Cooper Companies and 16 mentions for Medline. Medline's average media sentiment score of 0.89 beat Cooper Companies' score of 0.51 indicating that Medline is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cooper Companies
10 Very Positive mention(s)
5 Positive mention(s)
5 Neutral mention(s)
7 Negative mention(s)
0 Very Negative mention(s)
Positive
Medline
6 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Cooper Companies beats Medline on 8 of the 15 factors compared between the two stocks.

How does Medline compare to Align Technology?

Medline (NASDAQ:MDLN) and Align Technology (NASDAQ:ALGN) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Medline currently has a consensus target price of $46.08, indicating a potential upside of 22.28%. Align Technology has a consensus target price of $193.08, indicating a potential upside of 18.12%. Given Medline's stronger consensus rating and higher probable upside, research analysts clearly believe Medline is more favorable than Align Technology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medline
2 Sell rating(s)
4 Hold rating(s)
23 Buy rating(s)
0 Strong Buy rating(s)
2.72
Align Technology
0 Sell rating(s)
8 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.59

88.4% of Align Technology shares are owned by institutional investors. 0.8% of Medline shares are owned by company insiders. Comparatively, 0.8% of Align Technology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Medline had 11 more articles in the media than Align Technology. MarketBeat recorded 16 mentions for Medline and 5 mentions for Align Technology. Align Technology's average media sentiment score of 1.41 beat Medline's score of 0.89 indicating that Align Technology is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Medline
6 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Align Technology
4 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Align Technology has a net margin of 11.83% compared to Medline's net margin of 1.84%. Align Technology's return on equity of 15.96% beat Medline's return on equity.

Company Net Margins Return on Equity Return on Assets
Medline1.84% 8.21% 4.03%
Align Technology 11.83%15.96%10.48%

Medline has higher revenue and earnings than Align Technology. Align Technology is trading at a lower price-to-earnings ratio than Medline, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medline$28.43B1.74$1.16B$0.4485.64
Align Technology$4.03B2.86$410.35M$6.8723.79

Summary

Medline and Align Technology tied by winning 8 of the 16 factors compared between the two stocks.

Get Medline News Delivered to You Automatically

Sign up to receive the latest news and ratings for MDLN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MDLN vs. The Competition

MetricMedlineHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$51.52B$5.98B$7.82B$11.74B
Dividend YieldN/A1.68%2.47%4.47%
P/E Ratio32.3736.1232.9827.06
Price / Sales1.745.398.565.70
Price / Cash23.0923.6221.0121.90
Price / Book2.564.174.463.72
Net Income$1.16B$143.92M$3.52B$393.10M
7 Day Performance-10.63%-5.48%-5.93%-5.76%
1 Month Performance4.78%-3.68%-4.57%-7.14%
1 Year PerformanceN/A-0.10%-1.93%-7.46%

Medline Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MDLN
Medline
3.7947 of 5 stars
$37.68
-3.8%
$46.08
+22.3%
N/A$51.52B$28.43B32.3745,000
ALC
Alcon
3.4017 of 5 stars
$71.98
-0.7%
$82.32
+14.4%
-3.1%$35.58B$10.98B52.5125,942
WST
West Pharmaceutical Services
3.7748 of 5 stars
$412.97
+0.0%
$424.67
+2.8%
+57.8%$28.77B$3.40B46.3510,800
SOLV
Solventum
2.0318 of 5 stars
$87.80
-0.9%
$90.27
+2.8%
+13.4%$14.90B$8.33B98.6420,000
COO
Cooper Companies
3.5872 of 5 stars
$62.38
-0.9%
$68.60
+10.0%
-14.9%$11.88B$4.24B21.3115,000

Related Companies and Tools


This page (NASDAQ:MDLN) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners